Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Update

Lyell Immunopharma, Inc. (NASDAQ:LYEL) was the target of a large growth in short interest in June. As of June 15th, there was short interest totalling 24,150,000 shares, a growth of 19.6% from the May 31st total of 20,200,000 shares. Approximately 20.4% of the company’s stock are short sold. Based on an average trading volume of 788,600 shares, the days-to-cover ratio is presently 30.6 days.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. ProShare Advisors LLC increased its stake in shares of Lyell Immunopharma by 9.3% during the 1st quarter. ProShare Advisors LLC now owns 48,986 shares of the company’s stock worth $109,000 after purchasing an additional 4,170 shares during the last quarter. Profund Advisors LLC increased its stake in shares of Lyell Immunopharma by 20.0% during the 3rd quarter. Profund Advisors LLC now owns 73,442 shares of the company’s stock worth $108,000 after purchasing an additional 12,225 shares during the last quarter. Public Employees Retirement System of Ohio increased its stake in shares of Lyell Immunopharma by 109.7% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 27,203 shares of the company’s stock worth $40,000 after purchasing an additional 14,229 shares during the last quarter. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Lyell Immunopharma during the 4th quarter worth about $31,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Lyell Immunopharma by 67.7% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 48,855 shares of the company’s stock worth $109,000 after purchasing an additional 19,718 shares during the last quarter. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on LYEL shares. Bank of America cut their price objective on shares of Lyell Immunopharma from $9.00 to $6.00 and set a “buy” rating on the stock in a research report on Thursday, June 27th. HC Wainwright reiterated a “neutral” rating and issued a $1.00 price target (down from $6.00) on shares of Lyell Immunopharma in a research note on Thursday, June 27th.

Lyell Immunopharma Price Performance

LYEL stock traded down $0.07 during midday trading on Tuesday, hitting $1.51. The company’s stock had a trading volume of 934,752 shares, compared to its average volume of 1,033,032. Lyell Immunopharma has a twelve month low of $1.18 and a twelve month high of $3.41. The company’s fifty day moving average price is $2.36 and its 200 day moving average price is $2.23. The stock has a market capitalization of $384.96 million, a P/E ratio of -1.68 and a beta of -0.52.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings results on Monday, May 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.04). Lyell Immunopharma had a negative net margin of 335,794.09% and a negative return on equity of 33.92%. Equities analysts expect that Lyell Immunopharma will post -0.85 EPS for the current fiscal year.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.